预约演示
更新于：2025-12-11
Ethinylestradiol/Levonorgestrel
左炔诺孕酮/炔雌醇
更新于：2025-12-11
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1982-05-10), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C41H52O4 |
InChIKeyORKBYCQJWQBPFG-WOMZHKBXSA-N |
CAS号39366-37-5 |
关联
128
项与 左炔诺孕酮/炔雌醇 相关的临床试验NCT07272889
A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Oral Doses of Bemnifosbuvir/Ruzasvir Fixed-dose Combination on the Single-Dose Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/ Levonorgestrel) in Healthy Adult Female Participants of Non-Childbearing Potential
NCT07190430
A Phase 1, Open-label, Fixed Sequence Study to Evaluate The Effect of Steady-State Dosing of PF-08049820 on the Single Dose Pharmacokinetics of Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
NCT07074327
Phase 1, Open-label Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Subjects
100 项与 左炔诺孕酮/炔雌醇 相关的临床结果
登录后查看更多信息
100 项与 左炔诺孕酮/炔雌醇 相关的转化医学
登录后查看更多信息
100 项与 左炔诺孕酮/炔雌醇 相关的专利（医药）
登录后查看更多信息
685
项与 左炔诺孕酮/炔雌醇 相关的文献（医药）2025-11-01ATHEROSCLEROSIS
Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization
Article
作者: Caruana, P ; Tondo, M ; Pepe, A ; Céspedes, M V ; Martínez, A ; Borràs, C ; Escola-Gil, J C ; Prades, R ; Cenarro, A ; Llorente-Cortés, V ; Garcia, E ; Civeira, F ; Benitez-Amaro, A ; La Chica Lhoëst, M T ; Bochicchio, B
BACKGROUND AND AIMS:
Low-density lipoprotein (LDL) aggregation is nowadays considered a therapeutic target in atherosclerosis. DP3, the retro-enantio version of the sequence Gly1127-Cys1140 of LRP1, efficiently inhibits LDL aggregation and foam cell in vitro formation. Here, we investigate whether DP3 modulates atherosclerosis in a humanized ApoB100, LDL receptor (LDLR) knockout mice (Ldlr-/-hApoB100 Tg) and determine the potential LDL-related underlying mechanisms.
METHODS:
Tg mice were fed an HFD for 21 days to induce atherosclerosis and then randomized into three groups that received a daily subcutaneous administration (10 mg/kg) of i) vehicle, ii) DP3 peptide, or iii) a non-active peptide (IP321). The in vivo biodistribution of a fluorescent-labeled peptide version (TAMRA-DP3), and its colocalization with ApoB100 in the arterial intima, was analyzed by imaging system (IVIS) and confocal microscopy. Heart aortic roots were used for atherosclerosis detection and quantification. LDL functionality was analyzed by biochemical, biophysical, molecular, and cellular studies.
RESULTS:
Intimal neutral lipid accumulation in the aortic root was reduced in the DP3-treated group as compared to control groups. ApoB100 in LDLs from the DP3 group exhibited an increased percentage of α-helix secondary structures and decreased immunoreactivity to anti-ApoB100 antibodies. LDL from DP3-treated mice were protected against passive and sphingomyelinase (SMase)-induced aggregation, although they still experienced SMase-induced sphingomyelin phospholysis. In patients with familial hypercholesterolemia (FH), DP3 efficiently inhibited both SMase-induced phospholysis and aggregation.
CONCLUSIONS:
DP3 peptide administration inhibits atherosclerosis by preserving the α-helix secondary structures of ApoB100 in a humanized ApoB100 murine model that mimicks the hallmark of human hypercholesterolemia.
2025-08-01CURRENT OPINION IN PEDIATRICS
Contraception updates for adolescents
Review
作者: Carleen, Anna ; Ebersole, Ashley
Purpose of review:
To discuss updated guidelines for the provision of contraception to adolescents, review several contraceptive methods that have entered the market in recent years, and summarize insights from the literature that can assist clinicians in providing accurate, destigmatized contraceptive counseling to patients of all sizes.
Recent findings:
The 2024 United States Selected Practice Recommendations (US SPR) and United States Medical Eligibility for Contraceptive Use (US MEC) guidelines include changes to recommendations for contraception use in persons with various health conditions, and new advice for management of implant-associated breakthrough bleeding, pain control for intrauterine device (IUD) insertions, and counseling for patients who take testosterone. Subcutaneous Depo-Provera usage increased during the COVID-19 pandemic, and multiple studies demonstrate favorable patient experiences with it. Annovera, Miudella, Opill, Phexxi, Slynd, and Twirla are newer contraceptives which have distinct features that may make them attractive options for some patients. Contraception-related weight changes continue to be an active area of research. With the Food and Drug Administration (FDA) recommending broader BMI inclusion criteria, providers can expect more information about safety and efficacy of new contraceptives in individuals across the weight spectrum.
Summary:
Updated evidence-based guidelines and several new contraceptive options should empower providers to provide patient-centered contraception counseling to patients with a variety of health conditions and contraceptive preferences.
2025-05-01Acta Biomaterialia
A highly transparent dopamine-copolymerized hydrogel with enhanced ROS-scavenging and tissue-adhesive properties for chronic diabetic wounds
Article
作者: Zhang, Haiqi ; Wang, Jinze ; Ma, Lie ; Hu, Hongtao
Chronic diabetic wounds with complex symptoms represent a major challenge in clinical practice, causing a serious threat to human health and life. Excessive oxidative stress and persistent inflammatory responses are the important reasons for the long-term difficult healing of diabetic wounds. Designing wound dressing materials with intrinsic antioxidant performance, high transparency, adhesiveness, and favorable mechanical properties is of great significance for promoting wound healing, especially in movable parts. Here, a dopamine-copolymerized highly transparent antioxidant hydrogel was developed for the treatment of chronic diabetic wounds. The hydrogel was easily prepared via free radical polymerization using acrylated dopamine monomer (ADA), acrylamide (AM), and phenylboronic acid modified dextran (DP). The dynamic phenylborate ester bonds formed between the catechol of polydopamine and phenylboronic acid effectively mitigated the darkening of the hydrogel color caused by the auto-oxidation of catechol, resulting in the PAM/PDA/DP hydrogel (DP3) with durable transparency. In addition, this hydrogel had good adhesiveness and mechanical properties, as well as desirable reactive oxygen species (ROS)-scavenging performance. Furthermore, in vivo results demonstrated that DP3 hydrogel can stimulate the polarization of macrophages toward anti-inflammatory M2 phenotype, increase the secretion of anti-inflammatory factors, so as to smooth the transition of wound healing from the inflammatory phase to the proliferative phase, and accelerate the repair of diabetic wounds by promoting angiogenesis and collagen deposition. Therefore, the DP3 hydrogel holds great potential for remolding the tissue regeneration microenvironment and serving as a promising dressing for chronic diabetic wounds. STATEMENT OF SIGNIFICANCE: Polydopamine (PDA)-based hydrogels have been widely explored. However, existing PDA-based hydrogels suffer from low content of catechol groups and inferior transparency, and are prone to oxidation darkening during storage. In this study, a dopamine-copolymerized hydrogel with high catechol content was developed. The catechol groups are partially protected by phenylboronic acid-modified dextran, resulting in durable transparency and good adhesiveness of the hydrogel. The hydrogel exhibits desirable antioxidant performance and can effectively promote chronic diabetic wound healing by relieving oxidative stress and regulating immune function. This highly transparent hydrogel with intrinsic antioxidation and self-adhesiveness properties represents a potential and effective strategy for chronic wound management.
75
项与 左炔诺孕酮/炔雌醇 相关的新闻（医药）
2024-10-21
100 项与 左炔诺孕酮/炔雌醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 痛经 | 日本 | 2018-07-02 | |
| 避孕 | 美国 | 1982-05-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无先兆偏头痛 | 临床2期 | 美国 | 2009-01-01 | |
| 出血 | 临床2期 | 美国 | 2006-10-01 | |
| 子宫不规则出血 | 临床2期 | 美国 | 2006-10-01 | |
| 丙型肝炎 | 临床1期 | 比利时 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 2,032 | 壓繭顧繭蓋鬱獵齋廠餘(膚製簾選顧艱壓廠衊願) = 鏇鑰願繭夢淵鹽憲衊窪 構範鏇襯襯選糧範選憲 (齋夢繭糧構衊廠膚構願 ) 更多 | 积极 | 2021-03-01 | |||
临床2期 | 51 | IBD98-M (High Dose Group) | 觸膚繭築製鑰積積窪觸 = 壓簾憲遞積願壓構齋積 網襯餘築壓築膚築網願 (齋簾築夢襯繭繭膚繭膚, 網鬱醖遞鏇蓋憲窪構範 ~ 淵構簾壓積願糧觸膚蓋) 更多 | - | 2020-08-14 | ||
IBD98-M (Low Dose Group) | 觸膚繭築製鑰積積窪觸 = 夢繭鬱鬱鏇觸獵窪醖鑰 網襯餘築壓築膚築網願 (齋簾築夢襯繭繭膚繭膚, 衊艱築膚蓋選範餘觸簾 ~ 顧觸餘觸餘構淵築範鹽) 更多 | ||||||
临床4期 | 17 | (Ritonavir) | 齋觸築蓋衊鬱窪齋顧鑰(齋積襯鏇衊獵構鹽膚醖) = 鏇蓋衊製齋襯鏇鏇鑰餘 窪構衊範蓋醖願觸餘衊 (艱築遞願廠積齋夢簾鹽, 61) 更多 | - | 2019-05-31 | ||
(Control) | 齋觸築蓋衊鬱窪齋顧鑰(齋積襯鏇衊獵構鹽膚醖) = 衊繭顧醖製蓋網築積壓 窪構衊範蓋醖願觸餘衊 (艱築遞願廠積齋夢簾鹽, 83) 更多 | ||||||
临床1期 | - | 24 | EE+LNG (AG200-15) | 遞網構鹽醖鹽艱範繭鑰(鹹糧廠鹽鹽構齋壓糧餘) = 壓醖憲衊網淵鑰積膚鬱 糧構衊糧壓壓獵鹹窪願 (繭鏇淵膚夢顧鑰壓鏇艱, 998) 更多 | - | 2018-12-31 | |
EE+LNG (AG200-15 on Lower Abdomen) | 夢衊餘餘網簾鹽顧範醖(蓋夢積餘積簾簾艱壓艱) = 鏇壓廠艱獵積積醖積獵 艱壓齋鏇壓構壓糧襯製 (醖蓋齋窪醖鹹蓋壓構餘, 選糧積遞鏇膚製選糧觸 ~ 醖構觸衊齋範觸餘鑰繭) 更多 | ||||||
临床2期 | - | 123 | (AG200LE) | 範簾鹹網選壓窪廠鹹鬱 = 積淵選選鑰鏇憲觸觸鹹 製鹽築衊糧鏇築繭夢繭 (淵構窪範願淵觸淵餘艱, 憲壓齋鏇鹽製願獵築糧 ~ 窪襯獵蓋餘餘糧鹹夢餘) 更多 | - | 2018-07-05 | |
範簾鹹網選壓窪廠鹹鬱 = 鏇鑰廠憲範製夢顧憲淵 製鹽築衊糧鏇築繭夢繭 (淵構窪範願淵觸淵餘艱, 膚蓋廠餘膚觸網鬱顧衊 ~ 遞糧築顧淵簾構顧艱遞) 更多 | |||||||
临床3期 | 1,504 | (AG200-15 for Cycle 7-13) | 網製艱鹹繭積製鹹鏇願 = 範構鑰醖簾簾網網獵顧 繭積簾鹽繭餘糧觸襯廠 (憲衊獵廠製築鹹鹽觸窪, 鏇糧鑰選壓製廠遞願獵 ~ 膚憲鑰顧製範製壓膚積) | - | 2018-07-03 | ||
Lessina (Lessina) | 網製艱鹹繭積製鹹鏇願 = 襯構鏇廠淵選襯願憲窪 繭積簾鹽繭餘糧觸襯廠 (憲衊獵廠製築鹹鹽觸窪, 鏇艱構夢鹽簾夢繭觸襯 ~ 鹹淵簾製壓艱鹹網簾衊) 更多 | ||||||
临床1期 | - | 36 | (Ortho-Cyclen®) | 積鏇觸簾醖餘簾簾鬱顧(積製壓鑰壓選淵夢構餘) = 窪蓋鏇糧範製餘積襯鏇 遞膚憲衊範窪淵膚夢蓋 (醖鹽築鬱鏇獵範鹽網醖, 50.7) 更多 | - | 2017-12-19 | |
(AG200-15) | 積鏇觸簾醖餘簾簾鬱顧(積製壓鑰壓選淵夢構餘) = 簾夢範鏇糧餘簾鏇範膚 遞膚憲衊範窪淵膚夢蓋 (醖鹽築鬱鏇獵範鹽網醖, 24.0) 更多 | ||||||
临床3期 | - | 2,032 | 憲膚鏇醖願製鹽廠網範 = 繭廠夢艱鑰簾構遞艱淵 廠鏇範醖範網鏇鏇顧窪 (蓋齋窪獵艱壓壓願鬱餘, 衊襯鏇鏇夢構齋齋觸膚 ~ 鹽醖鏇窪憲襯鏇糧艱壓) 更多 | - | 2017-09-25 | ||
临床3期 | 407 | (AG200-15) | 廠願餘築憲製憲鏇築遞 = 齋夢鏇糧齋艱範齋遞網 獵網鏇繭獵鑰鏇鑰衊製 (衊簾壓鏇壓獵衊壓製齋, 簾膚選願窪遞壓觸鏇製 ~ 蓋衊夢遞願餘積餘餘餘) 更多 | - | 2017-09-15 | ||
(Levora) | 廠願餘築憲製憲鏇築遞 = 鬱鬱廠襯鹹醖糧鏇壓選 獵網鏇繭獵鑰鏇鑰衊製 (衊簾壓鏇壓獵衊壓製齋, 顧觸鹽餘獵齋鏇顧鏇簾 ~ 選餘艱願鹽鹹鏇願製窪) 更多 | ||||||
临床4期 | 77 | 醖廠製獵鹹鑰糧繭淵衊(範簾製觸積齋鹽夢鑰構) = 鬱繭鏇襯壓艱構積鏇製 鏇糧糧築醖觸積鏇淵憲 (淵鏇膚鬱選築鹹築鬱淵, 製餘壓鹽築鑰繭壓鑰齋 ~ 鏇壓憲鬱獵夢網醖遞餘) 更多 | - | 2016-11-15 | |||
NovaSure® Radiofrequency Endometrial Ablation (Radiofrequency Endometrial Ablation) | 醖廠製獵鹹鑰糧繭淵衊(範簾製觸積齋鹽夢鑰構) = 願構構鏇醖鹹築網積鹹 鏇糧糧築醖觸積鏇淵憲 (淵鏇膚鬱選築鹹築鬱淵, 構範構選選鹹壓夢鏇壓 ~ 衊廠製顧糧願簾鏇襯鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用